[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"total-shoulder-arthroplasty\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:total-shoulder-arthroplasty":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":34,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100652223","continuous-interscalene-blocks-and-rebound-pain-100652223",false,"NCT07770165","Continuous Interscalene Blocks and Rebound Pain","Evaluation of the Effect of Continuous Interscalene Blocks on Rebound Pain Compared to Single-Shot Interscalene Blocks in Total Shoulder Arthroplasty : A Randomized-Controlled Trial","Inclusion Criteria:\n\n* Adults aged \\>18 years of age\n* ASA I-III\n* Scheduled for elective ambulatory total shoulder arthroplasty.\n\nExclusion Criteria:\n\n* ASA IV\n* Revision surgery\n* Contraindication to regional anesthesia (such as allergy to local anesthetics, systemic anticoagulation, local infection)\n* Preoperative chronic pain or opioid use\n* Preoperative drug dependency\n* Severe respiratory disease or contralateral diaphragmatic paralysis\n* Patient refusal.","ALL","18 Years",{"count":19,"type":20},154,"ESTIMATED","INTERVENTIONAL",[23],"NA","The primary objectives of this present study are to examine whether a continuous interscalene block of a total duration of 48 hours reduces the incidence of rebound pain comparatively to single-shot interscalene block, through the evaluation of the NRS scores at rest and on movement in the postoperative period at 24, 48, 72 and 96 hours as well as the total opioid consumption in the same timeframe for patients undergoing total shoulder arthroplasty.\n\nRebound pain has been defined in some studies as the \"the transition from well-controlled pain (numerical rating scale \\[NRS\\] ≤3) while the block is working to severe pain (NRS ≥7) within 24 h of block performance.\"",[26,27,28,29,30,31,32,33],"Total Shoulder Arthroplasty","Reverse Total Shoulder Arthroplasty","Interscalene Analgesia","Interscalene Blocks","Interscalene Nerve Block","Orthopedic Surgery Patients","Locoregional Anaesthesia","Rebound Pain",[35,36,37,38,26,27,33],"Interscalene","Nerve Block","Catheter","Continuous Interscalene Block","NOT_YET_RECRUITING","2026-08-17",{"date":42,"type":43},"2026-08-19","ACTUAL",{"date":45,"type":20},"2026-10",{"date":47,"type":20},"2027-05",{"name":49,"class":50},"University of Calgary","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":21,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":51},"100527095","phase-4-addition-of-a-pectoserratus-block-to-interscalene-block-in-patients-undergoing-total-shoulder-replacement-100527095","NCT06143306","Addition of a Pectoserratus Block to Interscalene Block in Patients Undergoing Total Shoulder Replacement","Inclusion Criteria:\n\n* Patients undergoing total shoulder arthroplasty or reverse total shoulder arthroplasty;\n* Patients aged 18-85 years old.\n\nExclusion Criteria:\n\n* Patients who have an exclusion to regional anesthesia such as pre-existing nerve damage to their brachial plexus or infection at the site of injection.\n* Patients who have exclusion to interscalene blockade such as severe lung disease.\n* Non-English speakers will be excluded because pain scales are not validated in other languages and there is lack of standardization of pain reporting.\n* Pregnant patients\n* Patients who are currently using opioids and patients with a diagnosis of chronic pain will be excluded.","85 Years",{"count":60,"type":20},110,[62],"PHASE4","The use of ISB in patients undergoing total shoulder arthroplasty (TSA) is the gold standard and results in significantly reduced pain scores and opioid use. However, patients still have pain and the majority require opioids postoperatively as the interscalene block (ISB) doesn't cover all of the dermatomes impacted during TSA. A pectoserratus block typically provides coverage to additional dermatomes that are impacted during TSA. Currently ISB is performed for every patient and perform a pectoserratus block to a portion of our patients undergoing TSA. The purpose of the study is to determine if the addition of the pectoserratus block to the ISB will results in improvement in pain control and decrease in opioid use, among patients undergoing TSA. This is a randomized prospective controlled trial. All patients undergoing total shoulder arthroplasty or reverse total shoulder arthroplasty aged 18-85 will be considered eligible for the study. Participants will be randomized to one of 2 treatment groups. Group 1 will receive an ultrasound guided pectoserratus block with 25 mL of 0.25% bupivacaine. Group 2 will be the control and receive an ultrasound guided pectoserratus block with 25 mL of saline. The drug will be administered by the anesthesiologist in-charge of the participant's care or an anesthesiologist who is a part of the study team.",[26],"RECRUITING","2026-03-16",{"date":68,"type":43},"2026-03-17",{"date":70,"type":43},"2024-08-14",{"date":72,"type":20},"2027-05-01",{"name":74,"class":50},"University of Minnesota"]